UPDATE: Tilray-sponsored brain-cancer study in Spain





Spanish researchers, with Tilray’s support, are hoping a cocktail of THC, CBD and the chemotherapy drug TMZ can shrink brain-cancer tumours and increase survival rates for patients suffering an aggressive form of brain cancer called glioblastoma multiforme.

Clinical-trial records updated on February 7, 2019 say the study is slated to start in March 2019.

Primary completion is expected by June 2020.

THC, CBD and chemo drug

Patients will be treated in the Spanish cities of Barcelona, Mallorca and Valencia.

Other sponsors and collaborators include:

  • Grupo Español de Investigación en Neurooncología
  • Medical Cannabis Bike Tour
  • Voices Against Brain Cancer

Positive results published 

The MZ/THC/CBD combo showed “a strong anti-tumoral effect” in experimental research published Biochemical Pharmacology in November 2018.

The Spanish researchers found that tumor-cell samples could be “therapeutically exploited for the management of Glioblastoma.”

photo of woman wearing yellow shirt

GW Pharmaceuticals study

The results of a clinical trial completed by GW Pharmaceuticals in 2016 have not been published, but the company subsequently announced a 83% survival rate among 21 patients,  compared with 53%  in the placebo group.




Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s